The effect of 1 mg of intravenous glucagon on platelet aggregation has been investigated in 12 normal subjects pre-treated with salicylate. All subjects demonstrated the expected inhibition of collagen-induced secondary aggregation but retained the normal adenosine diphosphate (ADP)-induced primary aggregation phase 18 h after the salicylate therapy (600–1,200 mg). Subsequent administration of glucagon caused a significant increase in the ADP-induced primary aggregation phase in the 12 subjects. This data indicates that glucagon increases the reactivity of platelets to ADP and may help to explain the common clinical association of raised plasma glucagon, increased platelet aggregation and vascular disease.
This content is only available via PDF.
© 1980 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.